Quantification of contrast-uptake as imaging biomarker for disease progression of renal cell carcinoma after tumor ablation

Acta Radiol. 2020 Dec;61(12):1708-1716. doi: 10.1177/0284185120909964. Epub 2020 Mar 26.

Abstract

Background: The prognosis of patients with renal cell carcinoma (RCC) depends greatly on the presence of extra-renal metastases.

Purpose: To investigate the value of total tumor volume (TTV) and enhancing tumor volume (ETV) as three-dimensional (3D) quantitative imaging biomarkers for disease aggressiveness in patients with RCC.

Material and methods: Retrospective, HIPAA-compliant, IRB-approved study including 37 patients with RCC treated with image-guided thermal ablation during 2007-2015. TNM stage, RENAL Nephrometry Score, largest tumor diameter, TTV, and ETV were assessed on cross-sectional imaging at baseline and correlated with outcome measurements. The primary outcome was time-to-occurrence of extra-renal metastases and the secondary outcome was progression-free survival (PFS). Correlation was assessed using a Cox regression model and differences in outcomes were shown by Kaplan-Meier plots with significance and odds ratios (OR) calculated by Log-rank test/generalized Wilcoxon and continuity-corrected Woolf logit method.

Results: Patients with a TTV or ETV > 5 cm3 were more likely to develop distant metastases compared to patients with TTV (OR 6.69, 95% confidence interval [CI] 0.33-134.4, P=0.022) or ETV (OR 8.48, 95% CI 0.42-170.1, P=0.016) < 5 cm3. Additionally, PFS was significantly worse in patients with larger ETV (P = 0.039; median PFS 51.87 months vs. 69.97 months). In contrast, stratification by median value of the established, caliper-based measurements showed no significant correlation with outcome parameters.

Conclusion: ETV, as surrogate of lesion vascularity, is a sensitive imaging biomarker for occurrence of extra-renal metastatic disease and PFS in patients with RCC.

Keywords: Renal cell carcinoma; biomarkers; metastases; prognosis; tumor volume.

MeSH terms

  • Ablation Techniques
  • Adult
  • Aged
  • Aged, 80 and over
  • Biomarkers, Tumor / pharmacokinetics*
  • Carcinoma, Renal Cell / diagnostic imaging*
  • Carcinoma, Renal Cell / surgery*
  • Contrast Media / pharmacokinetics*
  • Disease Progression
  • Female
  • Humans
  • Imaging, Three-Dimensional
  • Kidney Neoplasms / diagnostic imaging*
  • Kidney Neoplasms / surgery*
  • Male
  • Middle Aged
  • Neoplasm Staging
  • Radiography, Interventional*
  • Retrospective Studies
  • Sensitivity and Specificity
  • Tumor Burden
  • Ultrasonography, Interventional*

Substances

  • Biomarkers, Tumor
  • Contrast Media